2022-05-23 | NYSE: ABBV | Press release
New York, New York–(Newsfile Corp. – May 23, 2022) – The law firm Klein announces that a class action lawsuit has been filed on behalf of shareholders of AbbVie Inc. (NYSE: ABBV) alleging that the company has violated federal securities laws.
Class period: April 30, 2021 for August 31, 2021
Lead Applicant Deadline: June 6, 2022
No obligation or cost to you.
Learn more about your recoverable losses in ABBV:
NEWS AbbVie Inc. – ABBV NEWS
CLASS ACTION CASE DETAILS: The filed complaint alleges that AbbVie Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) safety concerns regarding Pfizer Inc.’s drug Xeljanz extended to Pfizer’s drug Abbvie Rinvoq and other medicines that inhibit the Janus kinase enzyme; (2) as a result, it was likely that the United States Food and Drug Administration would require additional safety warnings for Rinvoq and delay approval of additional therapeutic indications for Rinvoq; and (3) therefore, defendants’ statements regarding the company’s business, operations and prospects lacked a reasonable basis.
WHAT THIS MEANS FOR YOU AS A SHAREHOLDER: If you have suffered a loss in AbbVie, you have up to June 6, 2022 ask the court to obtain the status of principal plaintiff. Your ability to participate in any collection does not require you to serve as the lead plaintiff.
AT NO CHARGE TO YOU: If you purchased AbbVie securities during the relevant period, you may be entitled to compensation without payment of out-of-pocket expenses.
ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigation involving financial fraud across the country. Klein Law Firm is a litigation firm with experience in a wide range of areas, including securities law, corporate finance and commercial litigation. Since 2011, our experienced lawyers have achieved superior results for our clients with a personalized approach. Lawyer advertisement. Prior results do not guarantee similar results.
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/125030